From: VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Tumor Type | # of Tumors | % VEGFR2 Positive | % VEGFR2 Negative |
---|---|---|---|
SW480 xenograft | 4 | 60 ± 10.57a | 40 ± 12.61c |
Clinical colorectal carcinoma | 36 | 60 ± 3.06a | 40 ± 2.54c |
WM239 xenograft | 10 | 91.96 ± 3.01b | 8.04 ± 0.41d |
Clinical metastatic melanoma | 14 | 93 ± 3.29b | 7 ± 0.33d |